kabutan

CanBas Co.,Ltd.(4575) Summary

4575
TSE Growth
CanBas Co.,Ltd.
864
JPY
+19
(+2.25%)
Jan 29, 3:05 pm JST
5.64
USD
Jan 29, 1:05 am EST
Result
PTS
outside of trading hours
864.3
Jan 29, 3:01 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.64
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
845 JPY 5.51 USD
Previous Close Jan 28
845 JPY 5.53 USD
High Jan 29, 9:24 am
869 JPY 5.68 USD
Low Jan 29, 9:01 am
838 JPY 5.47 USD
Volume
127,900
Trading Value
0.11B JPY 0.72M USD
VWAP
858.87 JPY 5.61 USD
Minimum Trading Value
86,400 JPY 564 USD
Market Cap
0.02T JPY 0.11B USD
Number of Trades
440
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
1,266
1-Year High Aug 21, 2025
19,409
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 1,368,400
Jan 16, 2026 0 1,307,000
Jan 9, 2026 0 1,311,900
Dec 26, 2025 0 1,312,700
Dec 19, 2025 0 1,343,700
Company Profile
CanBas Co., Ltd. is a drug discovery venture specializing in anticancer drug development. Its primary source of income is research and development support funds. The company is actively seeking partnership opportunities.
Sector
Pharmaceuticals
CanBas Co., Ltd. is a drug discovery venture focusing on basic research, early clinical development, and late-stage clinical development of anticancer drugs. Leveraging its unique drug discovery approach, the company has a development pipeline consisting of multiple drug candidate compounds. CanBas utilizes external specialized institutions and a scientific advisory board, aiming for synergy by combining in-house development with strategic partnerships with pharmaceutical companies. The company's lead compound, CBP501, is currently undergoing Phase 2 clinical trials in combination with immune checkpoint inhibitor antibodies. CBS9106 has been licensed to a U.S. company and is progressing through clinical development. In addition to these, CanBas is conducting exploratory research on multiple novel candidate compounds. The company's immediate priorities are accelerating the development of CBP501 and maximizing its chances of success, while continuing basic research to deepen understanding of existing pipelines and generate next-generation pipelines. Continuous fundraising through direct financing is also positioned as one of the company's challenges and strategies to support these efforts.